MapLight Therapeutics Announces Completion of Dosing in Phase 1 Study of Therapy for Social Deficit in Autism Spectrum Disorder
Excerpt from the Press Release:
SAN FRANCISCO, Nov. 23, 2020 /PRNewswire/ — MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1 clinical trial evaluating the safety of ML-004, a selective serotonin receptor agonist. Based on results from the study to date, ML-004, which MapLight intends to evaluate for the treatment of deficits in sociability and irritability seen in individuals with autism spectrum disorder (ASD), appears to be well tolerated at all dose levels evaluated.
“The completion of dosing in the company’s first Phase 1 trial is an important milestone for MapLight Therapeutics,” stated Christopher Kroeger, M.D., MBA, Chief Executive Officer and Founder. “The data collected in this trial to date support the safety and tolerability of sustained dosing at levels well above what we predict will be required to treat patients with ASD. MapLight is excited to announce the completion of this initial step in developing what it hopes may be the first approved drug to treat social deficit in these patients.”
Click the button below to continue reading the Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?